Table 3.
Template DNA per μl | Expected quantification in 2 μl | Observed quantification with percent change over expected | |||||||||||
E2 | E6 | HMBS | E2/E6 | E6 per diploid genome | E2 | E6 | HMBS | E2/E6 | E6 per diploid genome | ||||
51 ng gDNA 10 pg pSP64 HPV16 | 760,000 | 760,000 | 28,571 | 1 | 53 | 893,063 | +17.5% | 616,115 | -18.9% | 49,816 | +74.4% | 1.4 | 25 |
11 ng gDNA 2.16 pg pSP64 HPV16 | 163,922 | 163,922 | 6,163 | 1 | 53 | 208,404 | +27.1% | 172,423 | +5.2% | 7,437 | +20.7% | 1.2 | 46 |
3 ng gDNA 60 fg pSP64 HPV16 | 44,665 | 44,665 | 1,679 | 1 | 53 | 26,956 | -39.7% | 40,597 | -9.1% | 1,047 | +37.6% | 0.7 | 78 |
Peripheral blood lymphocyte gDNA was spiked with a known quantity of HPV16 DNA (in the pSP64-HPV16 plasmid). The template DNA was serially diluted, and absolute amounts were measured by spectrophotometry. The template DNA values are given in the first column of the Table. The anticipated gene copy numbers for E2, E6 and HMBS were derived, and are shown in the 'Expected quantification' section. qPCR of the serially diluted samples was performed, and the observed gene copy numbers are reported in the 'Observed quantification' section.